Cure My Disease

Don't miss your cure!

 Log in / Sign up

Probiotic secretions take aim at MRSA's armor in wound infections

NCT ID NCT07796555

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study examines whether a probiotic's cell-free supernatant, a liquid containing its secreted products, can alter the behavior of methicillin-resistant Staphylococcus aureus (MRSA) isolated from surgical site infections. Researchers will collect 100 MRSA samples from patients with postoperative wound infections and test how the supernatant affects genes linked to biofilm formation and antibiotic resistance. The goal is to understand whether probiotic secretions could weaken MRSA's ability to persist and resist treatment, which might inform future infection-control strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic cell-free supernatant (CFS) applied to clinical MRSA isolates in the laboratory
What this could lead to
If the probiotic supernatant suppresses biofilm and resistance genes, it could point toward new topical or preventive strategies against hard-to-treat MRSA wound infections.
What could go wrong
This is a laboratory study on bacterial samples, not a patient treatment trial. Any effect seen in the lab may not translate to real infections, and the supernatant is not yet a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

wound swabs and pus specimens will be collected under complete aseptic conditions from patients with suspected SSIs using sterile swabs. The samples will be transferred immediately to the microbiology laboratory to be processed

Ages

6 months to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of any age diagnosed with postoperative SSIs. * Clinical isolates from SSIs identified as MRSA. Exclusion Criteria: * Any microorganism isolated from SSIs other than MRSA. * Prior administration of postoperative antibiotics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methicillin-resistant staphylococcus aureus infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

methicillin-resistant staphylococcus aureus infectious disease staphylococcus aureus infection Surgical Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Staphylococcal aureus infection Surgical site infection (SSI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.